

PATENT
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U. S. Patent No. : US 7,317,026
Issue Date: : January 8, 2008
Serial No. : 10/728,340
First Named Inventor : Dale M. Edgar
Attorney Docket No. : X17615B (20712-501 CON)

REVOCATION OF POWER OF ATTORNEY WITH NEW POWER OF ATTORNEY
CHANGE OF CORRESPONDENCE ADDRESS, AND
CERTIFICATE UNDER 37 CFR 3.73(b)

Mail Stop Post Issue
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
Sir:

I hereby revoke all previous powers of attorney given in the above-identified patent.

I hereby appoint the practitioners associated with the Customer Number **25885**.

Please change the correspondence address for the above-identified patent to the address associated with the Customer Number **25885**.

Please change the Attorney Docket No. for the above-identified patent to X17615B.

US Patent No.:

HYPNION, INC., a Delaware Corporation, with the address Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, certifies that it is the assignee of the entire right, title and interest in the patent identified above by virtue of:

A. An assignment from the inventors of the patent identified above, which was recorded in the Patent and Trademark Office at Reel 014231, Frame 0124.

B. A change of assignee address, which was recorded in the Patent and Trademark Office at Reel 017201, Frame 0782.

AND

C. A merger document, which was recorded in the Patent and Trademark Office at Reel 022071, Frame 0589.

The undersigned (whose title is supplied below) is empowered to sign this certificate on behalf of the assignee as evidenced by the attached delegations of authority (Hypnion, Inc. to Douglas K. Norman and Douglas K. Norman to Lilly Practitioners).

Respectfully submitted,

/Thomas E. Jackson/

Thomas E. Jackson
Patent Counsel
Registration No. 33064
Phone: 317/277-3735

Eli Lilly and Company
Patent Division/
P.O. Box 6288
Indianapolis, Indiana 46206-6288

December 8, 2009

Attachments (2)

**Delegation of Authority Concerning
Certain Patent Matters**

Pursuant to the authority granted to me by Andrew M. Dahlberg, President of Hypnion, Inc. ("Hypnion"), a wholly owned subsidiary of Eli Lilly and Company, in a document dated September 16, 2008, (a copy which is attached as Appendix A), I delegate to each of the following persons:

ANDERSON, Arvie J.	45,263	KOIVUNIEMI, Paul J.	31,533
APELGREN, Lynn D.	45,341	LEE, Robert E.	27,919
ARMITAGE, Robert A.	27,417	LEEDS, James P.	35,241
BARRETT, Brian P.	39,597	LENTZ, Nelsen L.	38,537
BIRCH, Gary M.	48,881	McGRAW, Elizabeth A.	44,646
CALTRIDER, Steven P.	36,467	MARTINEZ, Alejandro	58,163
CANTRELL, Paul R.	36,470	MYERS, James B.	42,021
CASTETTER, Andrea	63,964	NORMAN, Douglas K.	33,267
CLEVELAND, John A., Jr.	50,697	PALMBERG, Arleen	40,422
CORNEGLIO, Donald L.	30,741	PLANT, Thomas G.	35,784
COX, Gregory A.	47,504	PREIN, Edward J.	37,212
DAVIS, Paula K.	47,514	RAO, Zhigang	63,878
DEMEMETER, John C.	30,167	SALES, James	33,773
DESAI, Manisha A.	43,585	SHARP, Robert L.	45,609
DINGESS-HAMMOND, Elizabeth	63,996	STEWART, Mark J.	43,936
EBERSOLE, Ted	51,641	TITUS, Robert D.	40,206
GAYLO, Paul J.	36,808	TUCKER, R. Craig	45,165
GINAH, Francis O.	44,712	TUCKER, Tina M.	47,145
HAMILTON, Amy E.	33,894	VORNDRAN-JONES, MaCharri	36,711
HASON, Averie	57,722	VOY, Gilbert T.	43,972
HOSTETTLER, Danica	51,820	WELCH, Lawrence T.	29,487
JACKSON, Thomas E.	33,064	WILSON, Alexander	45,782
JIVRAJ, Sanjay	60,806	WINTER, Mark A.	53,782
JOHNSON, Robert B.	63,813	WISKERCHEN, MaryAnn	45,511
KELEHER, Gerald P.	43,707	WOOD, Dan L.	48,613
KELLEY, James J.	41,888	WOODS, Nicole	56,579
		XIE, Congping	57,817

all of whom are registered to practice before the United States Patent and Trademark Office and are employees of Eli Lilly and Company, the authority to approve and execute for and on behalf of Hypnion, documents in connection with patent matters relating to:

- (i) the institution, prosecution, and completion of proceedings directed towards the issuance of patents;
- (ii) the amendment, restriction, renewal, reissue, revival, maintenance, restoration, cancellation, extension, and abandonment of patents and of applications for patents;
- (iii) the institution, prosecution, and termination of proceedings of interference, opposition, revocation, and nullification, including the filing of preliminary statements, concessions of priority, disclaimers, abandonments of contests, and abandonments of the invention;

(iv) the settlement of patent proceedings of interference, opposition, revocation, and nullification, subject to prior approval by the Senior Vice President and General Counsel of the Company;


(v) the filing of statutory disclaimers;

(vi) the institution, prosecution, and termination of appellate proceedings; and

(vii) the granting and the revocation of powers of attorney in connection with any of the foregoing, except there shall be no authority to revoke any power of attorney held by the Vice President and General Patent Counsel, Lilly Research Laboratories (a division of Eli Lilly and Company).

Dated:

November 19, 2009



Douglas K. Norman

Douglas K. Norman

Vice President and General Patent Counsel

**Delegation of Authority Concerning
Certain Patent Matters**

On behalf of Hypnion, Inc. (Hypnion), a Delaware corporation with a principal place of business at Lilly Corporate Center, Indianapolis, Indiana 46285, (formerly at 500 Patriot Way, Lexington, Massachusetts 02421), a wholly-owned subsidiary of Eli Lilly and Company, an Indiana corporation with a principal place of business at Lilly Corporate Center, Indianapolis, Indiana 46285, I delegate to Douglas K. Norman, General Patent Counsel of Eli Lilly and Company:

Authority to approve and execute for and on behalf of Hypnion, documents in connection with patent matters relating to:

- (i) the institution, prosecution, and completion of proceedings directed towards the issuance of patents;
- (ii) the amendment, restriction, renewal, reissue, revival, maintenance, restoration, cancellation, extension, and abandonment of patents and of applications for patents;
- (iii) the institution, prosecution, and termination of proceedings of interference, opposition, revocation, and nullification, including the filing of preliminary statements, concessions of priority, disclaimers, abandonments of the contents, and abandonments of the invention;
- (iv) the settlement of patent proceedings of interference, opposition, revocation, and nullification, subject to prior approval by the Senior Vice President and General Counsel of Eli Lilly and Company;
- (v) the filing of statutory disclaimers;
- (vi) the institution, prosecution, and termination of appellate proceedings; and
- (vii) the granting and the revocation of powers of attorney in connection with any of the foregoing.

Dated: September 16, 2008



Andrew M. Dahlem
President, Hypnion, Inc.